Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction

Autor: Gerardo Umanzor, Hope S Rugo, Francisco J Barrios, R H Vasallo, Marco A Chivalan, S Bejarano, Julio Roberto Ramirez, Luis Fein, R D Kowalyszyn, D L Cutler, D Kramer, H Wang, R MF Kwan

Publikováno v: Cancer Research. 82:P1-16

Background: IVPac is widely used to treat patients with breast cancer. oPac+E is oral paclitaxel in combination with Encequidar, an oral, minimally absorbed, specific p-glycoprotein inhibitor that enables the absorption of oral paclitaxel. Results of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d38383fb942a80deb271ccf0db35570
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-05

Abstract PS13-06: Lower rates of neuropathy with oral paclitaxel and encequidar (oPac+E) compared to IV paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001

Autor: Suyapa A. Bejarano, F J Barrios, R H Vasallo, D Kramer, G Umanzor, R Mf Kwan, J Goldfinch, T Moore, M A Chivalan, D L Cutler, Luis Fein, R D Kowalyszyn, J R Ramirez, Hui Wang, Hope S. Rugo

Publikováno v: Cancer Research. 81:PS13-06

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with IVPac. Primarily sensory, CIPN is an often irreversible condition primarily affecting the hands and feet associated with pain, numbness,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83c2ef5eb2fc0f66862fa6d73b4aec08
https://doi.org/10.1158/1538-7445.sabcs20-ps13-06

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Autor: Antonarakis ES; Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, MD 21231-1000, USA. eantona1@jhmi.edu, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2013 Apr; Vol. 71 (4), pp. 883-92. Date of Electronic Publication: 2013 Jan 13.